{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:59:12Z","timestamp":1794002352334,"version":"4.8.0"},"reference-count":42,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Bone metastases in patients can cause significant quality-of-life declines due to skeletal-related events (SREs). SRE is defined as the occurrence of radiotherapy for bone pain, pathologic fracture, bone surgery, spinal cord compression, or hypercalcemia. Bone-modifying agents (BMAs), such as denosumab and zoledronic acid, are crucial in reducing the frequency and severity of SREs. The inhibition of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors has emerged as the standard treatment for hormone receptor-positive metastatic breast cancer, demonstrating significant improvements in survival outcomes. This study aims to compare the effectiveness of denosumab and zoledronic acid in preventing SRE in patients receiving CDK4\/6 inhibitors with endocrine therapy. Materials and Methods: This retrospective study included 328 patients diagnosed with bone metastatic breast cancer receiving first-line CDK4\/6 inhibitor therapy (palbociclib or ribociclib). Patients were assigned to receive either subcutaneous denosumab or intravenous zoledronic acid every 4 weeks. Time to the first skeletal-related event post bone-modifying agent initiation, SRE incidence, and the safety data were evaluated. The data were analyzed using independent samples t-tests, chi-square tests, and Kaplan\u2013Meier methods for time-to-event data. Results: In the denosumab group, the median time to the first skeletal-related event was significantly longer than in the zoledronic acid group (44.55 months and 29.16 months, respectively). Denosumab treatment was associated with a statistically significant reduction in the risk of developing the first SRE after bone-modifying agent initiation compared to zoledronic acid (HR: 0.56, p = 0.001). Additionally, ECOG PS and the number of metastatic bone sites were identified as independent prognostic factors for time to the first SRE. The safety profile was consistent with previous studies reported in the literature. Conclusions: Our study demonstrated that when used with CDK4\/6 inhibitors, denosumab is associated with a delay in SREs and a lower SRE incidence than zoledronic acid in patients with bone metastases. These findings support the efficacy of denosumab in preventing SREs and suggest that CDK4\/6 inhibitors may have distinct effects on the bone microenvironment, particularly when combined with denosumab.<\/jats:p>","DOI":"10.3390\/medicina61020360","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:36:22Z","timestamp":1739957782000},"page":"360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4\/6 Inhibitor Therapy"],"prefix":"10.3390","volume":"61","author":[{"given":"\u0130rem","family":"\u00d6ner","sequence":"first","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7992-4008","authenticated-orcid":false,"given":"Hicran","family":"An\u0131k","sequence":"additional","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bediz","family":"Kurt \u0130nci","sequence":"additional","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-5326","authenticated-orcid":false,"given":"P\u0131nar","family":"Kubilay Tolunay","sequence":"additional","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0182-3933","authenticated-orcid":false,"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclk\u00fc","family":"Yal\u00e7\u0131nta\u015f Arslan","sequence":"additional","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Kara\u00e7in","sequence":"additional","affiliation":[{"name":"Departmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.22867","article-title":"The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer","volume":"110","author":"Chia","year":"2007","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3349\/ymj.2013.54.5.1168","article-title":"Prognostic factors for patients with bone-only metastasis in breast cancer","volume":"54","author":"Ahn","year":"2013","journal-title":"Yonsei Med. J."},{"key":"ref_4","first-page":"97","article-title":"Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: A nationwide population-based cohort study in Denmark","volume":"5","author":"Svendsen","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-017-0362-4","article-title":"Hallmarks of Bone Metastasis","volume":"102","author":"Johnson","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bcp.13852","article-title":"Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss","volume":"85","author":"Mansinho","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12609-018-0295-6","article-title":"Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer","volume":"10","author":"Heeke","year":"2018","journal-title":"Curr. Breast Cancer Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113676","DOI":"10.1016\/j.bcp.2019.113676","article-title":"Multiple effects of CDK4\/6 inhibition in cancer: From cell cycle arrest to immunomodulation","volume":"170","author":"Bonelli","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tang, H., Yeo, D., De Souza, K., Ahmad, O., Shafiq, T., Ofor, O., Anand, A., Karim, S., Khan, S., and Madhusudan, S. (2023). Clinical Impact of CDK4\/6 Inhibitors in De Novo or PR\u2212 or Very Elderly Post-Menopausal ER+\/HER2\u2212 Advanced Breast Cancers. Cancers, 15.","DOI":"10.3390\/cancers15215164"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"212579","DOI":"10.7573\/dic.212579","article-title":"Palbociclib in metastatic breast cancer: Current evidence and real-life data","volume":"8","author":"Serra","year":"2019","journal-title":"Drugs Context"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: A review of subgroup analyses from the MONALEESA-2 trial","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Iuliani, M., Simonetti, S., Ribelli, G., Napolitano, A., Longo, U.G., Vincenzi, B., Orsaria, P., Denaro, V., Tonini, G., and Santini, D. (2022). Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052477"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Saleh, L., Ottewell, P.D., Brown, J.E., Wood, S.L., Brown, N.J., Wilson, C., Park, C., Ali, S., and Holen, I. (2023). The CDK4\/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo. Cancers, 15.","DOI":"10.3390\/cancers15082211"},{"key":"ref_21","unstructured":"Martelo, M.M. (2024). Efficacy of RANK pathway and CDK4\/6 inhibition in immune-competent luminal breast cancer models. [Master\u2019s Thesis, Universidade de Lisboa, Faculdade de Medicina]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"ref_25","first-page":"e20.00045","article-title":"Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials","volume":"4","author":"Frazer","year":"2020","journal-title":"J. Am. Acad. Orthop. Surg. Glob. Res. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12541","DOI":"10.1111\/ecc.12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J. Bone Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","article-title":"Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis","volume":"43","author":"Chen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1359\/jbmr.2004.19.7.1128","article-title":"Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6)","volume":"19","author":"Ogasawara","year":"2004","journal-title":"J. Bone Miner Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-020-05712-4","article-title":"Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate","volume":"182","author":"Miyashita","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10147-013-0643-5","article-title":"Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan","volume":"19","author":"Yamashiro","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J. Bone Miner Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00520-018-4060-1","article-title":"Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: Systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Menshawy","year":"2018","journal-title":"Support Care Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbo.2017.09.003","article-title":"The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2017","journal-title":"J Bone Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang","year":"2015","journal-title":"Oncologist"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1200\/jco.2013.31.15_suppl.9640","article-title":"Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials","volume":"31","author":"Lipton","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:37:59Z","timestamp":1760027879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["medicina61020360"],"URL":"https:\/\/doi.org\/10.3390\/medicina61020360","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}